AAPL VS APVO Stock Comparison

Performance

AAPL
100/100

AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

APVO
10/100

APVO returned -89.87% in the last 12 months. Based on SPY's performance of -20.61%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AAPL
78/100

38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.

APVO
75/100

1 analysts offer 12-month price targets for APVO. Together, they have an average target of 0, the most optimistic target put APVO at 0 within 12-months and the most pessimistic has APVO at 0.

Sentiment

AAPL
70/100

AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.

APVO
67/100

APVO had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 13.07 posts, 7.32 comments, and 21.67 likes per day.

Technicals

AAPL
18/100

AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

APVO
11/100

APVO receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

AAPL
100/100

AAPL has missed earnings 1 times in the last 20 quarters.

APVO
10/100

APVO has missed earnings 6 times in the last 20 quarters.

Profit

AAPL
76/100

Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.

APVO
19/100

Out of the last 20 quarters, APVO has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

AAPL
45/100

AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

APVO
36/100

APVO has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

Dividend

AAPL
50/100

AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.

APVO

"Dividend" not found for APVO

All score calculations are broken down here to help you make more informed investing decisions

Apple Inc. Summary

Nasdaq / AAPL

Technology

Consumer Electronics

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Aptevo Therapeutics Inc Summary

Nasdaq / APVO

Healthcare

Biotechnology

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Power up your portfolio